RPL4, ribosomal protein L4, 6124

N. diseases: 8; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
0.020 GeneticVariation disease BEFREE In a previous study, we reported that truncation of HP (2-20) (derived from the N-terminal region of Helicobacter pylori Ribosomal Protein L1 (RPL1)) at the N- (residues 2-3) and C-terminal (residues 17-20) truncated fragments to give HP (4-16) induces increased antibiotic activity against several bacterial strains without hemolysis. 21838696 2012
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
0.020 Biomarker disease BEFREE We investigated the in vitro antibiotic activity of the 19-amino acid antimicrobial peptide HP (2-20), derived from the N-terminus of Helicobacter pylori Ribosomal Protein L1 (RPL1), against antibiotic susceptible and resistant pathogens from a patient with gallstones. 16454670 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.010 Biomarker disease BEFREE SNHG7 contributed to HCC progression by regulating miR-122-5p and RPL4. 31545291 2019
CUI: C0036690
Disease: Septicemia
Septicemia
0.010 Biomarker disease BEFREE The relationship between pediatric sepsis and RPL4 and RPL9 needs further investigation. 27978524 2016
CUI: C0243026
Disease: Sepsis
Sepsis
0.010 Biomarker disease BEFREE The relationship between pediatric sepsis and RPL4 and RPL9 needs further investigation. 27978524 2016
CUI: C0272170
Disease: Shwachman syndrome
Shwachman syndrome
0.010 Biomarker disease BEFREE Reciprocal co-immunoprecipitation confirmed the interaction of SBDS with the large ribosomal subunit protein RPL4 and with DNA-PK and RPA70, two proteins with critical roles in DNA repair. 19602484 2009
CUI: C0008350
Disease: Cholelithiasis
Cholelithiasis
0.010 GeneticVariation disease BEFREE We investigated the in vitro antibiotic activity of the 19-amino acid antimicrobial peptide HP (2-20), derived from the N-terminus of Helicobacter pylori Ribosomal Protein L1 (RPL1), against antibiotic susceptible and resistant pathogens from a patient with gallstones. 16454670 2006
CUI: C0947622
Disease: Cholecystolithiasis
Cholecystolithiasis
0.010 GeneticVariation disease BEFREE We investigated the in vitro antibiotic activity of the 19-amino acid antimicrobial peptide HP (2-20), derived from the N-terminus of Helicobacter pylori Ribosomal Protein L1 (RPL1), against antibiotic susceptible and resistant pathogens from a patient with gallstones. 16454670 2006
CUI: C0749591
Disease: tonsillopharyngitis
tonsillopharyngitis
0.010 GeneticVariation disease BEFREE Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis. 14616688 2003